XML 17 R48.htm IDEA: XBRL DOCUMENT v2.4.0.8
Note 6 - Segment Reporting (Details) - Financial Information by Reporting Segment (USD $)
In Thousands, unless otherwise specified
3 Months Ended 9 Months Ended
Sep. 30, 2014
Sep. 30, 2013
Sep. 30, 2014
Sep. 30, 2013
Segment Reporting Information [Line Items]        
Net Revenue $ 59,711 $ 59,318 $ 154,584 $ 174,805
Gross Profit:        
Gross Profit 11,791 20,280 39,296 67,327
Operating expenses 19,608 20,054 50,255 52,767
Income (loss) from operations (7,817) 226 (10,959) 14,560
Non-operating income (expenses) (167) 109 (1,372) (115)
Income (loss) before income taxes (7,984) 335 (12,331) 14,445
Finished Pharmaceutical Products Segment [Member]
       
Segment Reporting Information [Line Items]        
Net Revenue 53,729 59,318 148,500 174,805
Gross Profit:        
Gross Profit 12,122 20,280 39,592 67,327
Active Pharmaceutical Ingredient Segment [Member]
       
Segment Reporting Information [Line Items]        
Net Revenue 5,982   6,084  
Gross Profit:        
Gross Profit $ (331)   $ (296)